(19) World Intellectual Property Organization International Bureau



) (TO THE BUILDING OF THE PROPERTY OF THE POST OF THE PROPERTY OF THE POST OF THE POST OF THE POST OF THE POST

(43) International Publication Date 7 April 2005 (07.04.2005)

PCT

(10) International Publication Number WO 2005/031302 A2

(51) International Patent Classification7:

G01N

(21) International Application Number:

PCT/US2004/030977

(22) International Filing Date:

22 September 2004 (22.09.2004)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data: 60/504,774

22 September 2003 (22.09.2003) U

(71) Applicant (for all designated States except US): UNIVER-SITY OF MARYLAND, BALTIMORE [US/US]; 520 West Lombard Street, Baltimore, MD 21201 (US).

- (72) Inventors; and
- (75) Inventors/Applicants (for US only): POLLI, James, E. [US/US]; 3524 Bucks County Court, Ellicott City, MD

21043-4143 (US). **HOAG, Stephen, W.** [US/US]; 205 Oak Forest Place, Baltimore, MD 21228-5624 (US).

- (74) Agents: VILLACORTA, Gilberto, M. et al.; Katten Muchin Zavis Rosenman, 1025 Thomas Jefferson Street, NW, East Lobby, Suite 700, Washington, DC 20007-5201 (US).
- (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI,

[Continued on next page]

(54) Title: DRUG AUTHENTICATION

Table 1. Level 1 Component and Composition Changes for Immediate Release Oral Solid Dosage

Forms	
Excipient	Percent Excipient (w/w) Out of Total Target Dosage Form Weight
Filler	+/- 5%
Disintegrant	
starch	+/- 3%
other	+/- 1%
Binder	+/- 0.5%
Lubricant	
calcium or magnesium stearate	+/- 0.25%
other ·	+/- 1%
Glidant	
talc	+/- 1%
other	+/- 0.1%
Film coat	+/- 1%

Tuble 2. Level 2 Component and Composition Changes for Immediate Release Oral Solid Dosage

Forms Excipient	Percent Excipient (w/w) Out of Total Target
	Dosage Form Weight
Filler	+/- 10%
Disintegrant	
starch	+/- 6%
other	+/- 2%
Binder	+/- 1%
Lubricant	
calcium or magnesium stearate	+/- 0.5%
other	+/- 2%
Glidant	
talc	+/- 2%
other	+/- 0.2%
Film coat	+/- 2%

(57) Abstract: A method is disclosed to verify and identify pharmaceutical products through their product signatures in order to combat counterfeiting and reduce dispensing errors, using methods such as near infrared spectroscopy. Furthermore, in order actively evade pharmaceutical product counterfeiting, a method is disclosed where an amount of one or more of the inactive ingredients is varied over time; the variation provides a different product signature, but falling within a level deemed permissible by a regulatory body.

WO 2005/031302 A2



FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

Published:

 without international search report and to be republished upon receipt of that report